Please login to the form below

Not currently logged in
Email:
Password:

Genmab

This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.

Janssen scores another expansion for new Darzalex combination in the US

Janssen scores another expansion for new Darzalex combination in the US

Darzalex, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.

Latest news

More from news
Approximately 7 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease. ... If approved, this would become Genmab’s third product on the market, behind Darzalex and

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. The creative aspect of this deal is that Seattle ... has retained an option to increase the Genmab royalties to double

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Genmab hires first chief operating officer Genmab hires first chief operating officer

    In his new role, Mancini will oversee all of Genmab’s commercial, corporate development, business development and information technology functions. ... operations during this transformational stage for Genmab,”said Jan van de Winkel, chief executive

  • EUSA Pharma appoints Rolf Hoffmann to its board EUSA Pharma appoints Rolf Hoffmann to its board

    Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number

  • Dr Jan van de Winkel joins Austrian biotech Hookipa Dr Jan van de Winkel joins Austrian biotech Hookipa

    Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice

  • Former Novartis exec joins Genmab Former Novartis exec joins Genmab

    Dr Judith Klimovsky becomes chief development officer. Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer. ... Jan van de Winkel, Genmab's chief executive, said: “We are very

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).

More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics